242 related articles for article (PubMed ID: 33590853)
1. In vitro selection of an RNA aptamer yields an interleukin-6/interleukin-6 receptor interaction inhibitor.
Ando T; Yamamoto M; Takamori Y; Tsukamoto K; Fuji D; Kawakami T
Biosci Biotechnol Biochem; 2021 Apr; 85(5):1170-1174. PubMed ID: 33590853
[TBL] [Abstract][Full Text] [Related]
2. Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor.
Gupta S; Hirota M; Waugh SM; Murakami I; Suzuki T; Muraguchi M; Shibamori M; Ishikawa Y; Jarvis TC; Carter JD; Zhang C; Gawande B; Vrkljan M; Janjic N; Schneider DJ
J Biol Chem; 2014 Mar; 289(12):8706-19. PubMed ID: 24415766
[TBL] [Abstract][Full Text] [Related]
3. Artificial aptamer that inhibits interleukin-23/interleukin-23 receptor interaction discovered via SELEX.
Takamori Y; Ando T; Sato M; Vedi S; Fuji D; Yokoyama T; Tsukamoto K; Yamamoto M; Kawakami T
Biochem Biophys Res Commun; 2022 Jul; 614():17-21. PubMed ID: 35567939
[TBL] [Abstract][Full Text] [Related]
4. RAID3--An interleukin-6 receptor-binding aptamer with post-selective modification-resistant affinity.
Mittelberger F; Meyer C; Waetzig GH; Zacharias M; Valentini E; Svergun DI; Berg K; Lorenzen I; Grötzinger J; Rose-John S; Hahn U
RNA Biol; 2015; 12(9):1043-53. PubMed ID: 26383776
[TBL] [Abstract][Full Text] [Related]
5. Is IL-6 a key cytokine target for therapy in COVID-19?
Jones SA; Hunter CA
Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
[TBL] [Abstract][Full Text] [Related]
6. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Agoramoorthy G
J Med Virol; 2020 Nov; 92(11):2260-2262. PubMed ID: 32462717
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells.
Meyer C; Eydeler K; Magbanua E; Zivkovic T; Piganeau N; Lorenzen I; Grötzinger J; Mayer G; Rose-John S; Hahn U
RNA Biol; 2012 Jan; 9(1):67-80. PubMed ID: 22258147
[TBL] [Abstract][Full Text] [Related]
8. Stabilized Interleukin-6 receptor binding RNA aptamers.
Meyer C; Berg K; Eydeler-Haeder K; Lorenzen I; Grötzinger J; Rose-John S; Hahn U
RNA Biol; 2014; 11(1):57-65. PubMed ID: 24440854
[TBL] [Abstract][Full Text] [Related]
9. On the role of bacterial metalloproteases in COVID-19 associated cytokine storm.
Földvári-Nagy L; Schnabel T; Dörnyei G; Korcsmáros T; Lenti K
Cell Commun Signal; 2021 Jan; 19(1):7. PubMed ID: 33441142
[TBL] [Abstract][Full Text] [Related]
10. SELEX of Cell-Specific RNA Aptamers.
Berg K; Magbanua E; Hahn U
Methods Mol Biol; 2016; 1380():21-32. PubMed ID: 26552813
[TBL] [Abstract][Full Text] [Related]
11. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.
Ali A; Kamjani MH; Kesselman MM
Recent Pat Antiinfect Drug Discov; 2020; 15(2):104-112. PubMed ID: 32962623
[TBL] [Abstract][Full Text] [Related]
12. Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome.
Chen LYC; Biggs CM; Jamal S; Stukas S; Wellington CL; Sekhon MS
Cell Rep Med; 2021 May; 2(5):100269. PubMed ID: 33899032
[TBL] [Abstract][Full Text] [Related]
13. In vitro display evolution of IL-6R-binding unnatural peptides ribosomally initiated and cyclized with m-(chloromethyl)benzoic acid.
Takamori Y; Ando T; Fuji D; Yokoyama T; Yamamoto M; Kawakami T
Biochem Biophys Res Commun; 2021 Jan; 535():47-53. PubMed ID: 33340765
[TBL] [Abstract][Full Text] [Related]
14. Selection of a DNA aptamer that binds 8-OHdG using GMP-agarose.
Miyachi Y; Shimizu N; Ogino C; Fukuda H; Kondo A
Bioorg Med Chem Lett; 2009 Jul; 19(13):3619-22. PubMed ID: 19450981
[TBL] [Abstract][Full Text] [Related]
15. Identification and Engineering of Aptamers for Theranostic Application in Human Health and Disorders.
Basu D; Chakraborty S; Pal R; Sharma TK; Sarkar S
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575825
[TBL] [Abstract][Full Text] [Related]
16. An improved SELEX technique for selection of DNA aptamers binding to M-type 11 of Streptococcus pyogenes.
Hamula CL; Peng H; Wang Z; Tyrrell GJ; Li XF; Le XC
Methods; 2016 Mar; 97():51-7. PubMed ID: 26678795
[TBL] [Abstract][Full Text] [Related]
17. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.
Corominas H; Castellví I; Diaz-Torné C; Matas L; de la Rosa D; Mangues MA; Moya P; Pomar V; Benito N; Moga E; Sosa NH; Casademont J; Domingo P
Medicine (Baltimore); 2021 May; 100(19):e25923. PubMed ID: 34106658
[TBL] [Abstract][Full Text] [Related]
18. A human epidermal growth factor receptor 3/heregulin interaction inhibitor aptamer discovered using SELEX.
Yokoyama T; Ando T; Iwamoto R; Fuji D; Yamamoto M; Kawakami T
Biochem Biophys Res Commun; 2021 May; 553():148-153. PubMed ID: 33770580
[TBL] [Abstract][Full Text] [Related]
19. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.
Du P; Geng J; Wang F; Chen X; Huang Z; Wang Y
Int J Med Sci; 2021; 18(6):1356-1362. PubMed ID: 33628091
[TBL] [Abstract][Full Text] [Related]
20. Aptamers and SELEX in Chemistry & Biology.
Famulok M; Mayer G
Chem Biol; 2014 Sep; 21(9):1055-8. PubMed ID: 25237853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
